Forte Biosciences, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net loss of $17.7 million for the third quarter, compared to a loss of $8.4 million in the same period last year, marking an increase of 110% year-over-year. For the nine months ended September 30, 2025, the net loss was $44.6 million, up from $28.3 million in the prior year. Operating expenses for the third quarter totaled $18.4 million, a substantial increase from $8.6 million in the previous year, driven primarily by heightened research and development costs associated with ongoing clinical trials.
Forte's total assets as of September 30, 2025, reached $97.1 million, a significant increase from $61.6 million at the end of 2024. This growth was largely attributed to a public offering completed in June 2025, which generated $75 million in gross proceeds. The company’s cash and cash equivalents rose to $93.4 million, up from $22.2 million at the end of 2024, providing a stronger liquidity position to support its clinical development efforts. The increase in cash reserves is expected to fund operations for at least the next twelve months.
In terms of operational developments, Forte is advancing its lead product candidate, FB102, which is currently in Phase 2 clinical trials for celiac disease and ongoing Phase 1b trials for vitiligo and alopecia areata. The company announced positive results from its Phase 1b study in celiac disease, which demonstrated significant improvements in key clinical endpoints. The successful completion of this trial has led to the initiation of a Phase 2 study, with topline results anticipated in 2026. The company is also exploring additional indications for FB102, including type 1 diabetes.
Forte's workforce has expanded, contributing to increased personnel-related expenses, which rose to $3.2 million for the third quarter, compared to $2.8 million in the same period last year. The company continues to build its infrastructure to support its clinical programs, which may lead to further fluctuations in general and administrative expenses. As of September 30, 2025, Forte had approximately 12.5 million shares outstanding, reflecting the impact of its recent capital raises.
Looking ahead, Forte anticipates continued operating losses as it invests in the development of FB102. The company is actively seeking additional funding sources to support its clinical trials and operational needs. Management has indicated that while the current cash position is sufficient for the near term, future capital requirements will depend on the progress of clinical trials and potential strategic partnerships. The company remains vigilant regarding macroeconomic factors that could impact its operations and funding strategies.
About Forte Biosciences, Inc.
Forte Biosciences is a clinical-stage biopharmaceutical company developing immunomodulatory therapies targeting autoimmune diseases. Its lead candidate, FB102, is a monoclonal antibody aimed at conditions like celiac disease, vitiligo, alopecia areata, and type 1 diabetes. The company focuses on innovative biologics, regulatory approval processes, and strategic partnerships to address unmet medical needs in autoimmune markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.